Radnet, INC Form 4 insider transactions

RadNet, Inc.'s President and CEO of Digital Health, Cornelis Wesdorp, sold 500 shares of common stock for $71.99 per share.

Norman R. Hames, RadNet's President and COO-West Operations, sold 5,000 shares of common stock for $71.1 per share as part of a pre-arranged 10b5-1 trading plan.

RadNet's Chief Information Officer, Ranjan Jayanathan, sold 65,598 shares of common stock at $67.5 per share.

RadNet's President and CEO of Digital Health, Cornelis Wesdorp, sold 1,500 shares of common stock for $66.98 per share.

RadNet's EVP and Chief Legal Officer, David Jeffrey Katz, sold 17,000 shares of common stock for approximately $68.31 per share.

RadNet, Inc. Director and EVP, Chief Science Officer Alma Gregory Sorensen reported a charitable donation of 5,600 shares of common stock, reducing direct beneficial ownership to 1,165,345 shares.

RadNet, Inc. Director David L. Swartz reported the acquisition of 2,699 shares of common stock, increasing his direct beneficial ownership to 176,766 shares.

RadNet, Inc. Director Gregory E. Spurlock is set to acquire 2,699 shares of common stock on June 10, 2025, as part of a pre-arranged Rule 10b5-1 plan, increasing his direct beneficial ownership to 5,290 shares.

RadNet, Inc. Director Lawrence L. Levitt has acquired 2,699 shares of common stock at a price of $0.00, increasing his total beneficial ownership to 167,656 shares.

RadNet, Inc. Director Laura Pastre Jacobs reported the acquisition of 2,699 shares of common stock at no cost, increasing her direct beneficial ownership to 27,007 shares.

Michael N. Murdock, Executive Vice President of Mergers and Acquisitions at RadNet, Inc., sold 11,132 shares of common stock for approximately $646,100 as part of a pre-arranged trading plan.

RadNet, Inc. Director and EVP, Chief Science Officer Alma Gregory Sorensen reported the acquisition of 10,436 shares of common stock on June 1, 2025, increasing total direct beneficial ownership to 1,170,945 shares.

Alma Gregory Sorensen, EVP, Chief Science Officer, and Director of RadNet, Inc. (RDNT), reported selling a total of 100,000 shares of the company's common stock in two separate transactions in May 2025.

Stephen Forthuber, Pres & COO-Eastern Operations at RadNet, Inc., reports the vesting and sale of restricted stock units.

Director Lawrence L. Levitt of RadNet, Inc. sold 5,000 shares of common stock at a price of $61.09 per share on May 16, 2025.

Norman Hames, Pres and COO-West Operations at RadNet, Inc., reports the vesting of restricted stock units and subsequent sale of common stock.

RadNet, Inc. announces the acquisition of iCAD Inc., a leader in AI-powered breast health solutions, to enhance patient diagnosis and outcomes globally.

RadNet's first quarter 2025 financial results were impacted by weather-related events, but the company still increased revenue and revised its full-year guidance upwards.

Alma Gregory Sorensen, EVP and Chief Science Officer of RadNet, Inc., reports acquisition and disposal of common stock on May 1, 2025.

RadNet plans to acquire iCAD, seeking to combine their strengths in diagnostic imaging, AI, and digital health solutions to enhance cancer screening and detection.

RadNet's DeepHealth is set to acquire iCAD for $103 million in an all-stock transaction, aiming to enhance AI-powered breast cancer screening capabilities.

RadNet plans to acquire iCAD for approximately $103 million in stock, integrating it into its DeepHealth subsidiary to accelerate AI-powered breast cancer detection.

RadNet is set to acquire iCAD in a stock-for-stock transaction, aiming to bolster its artificial intelligence capabilities in breast imaging and expand its market reach.

RadNet plans to acquire iCAD and integrate it into DeepHealth, RadNet's digital health business, to advance breast cancer screening.

RadNet plans to acquire iCAD for approximately $103 million in an all-stock deal to accelerate the adoption of AI in breast cancer screening.

RadNet plans to acquire iCAD to strengthen its DeepHealth leadership in AI-driven breast cancer solutions, expanding reach and enhancing financial performance.

RadNet, Inc. announces a definitive agreement to acquire iCAD, Inc., aiming to enhance AI-powered solutions in breast screening and expand its global reach.

RadNet has announced a definitive agreement to acquire iCAD, a leader in AI-powered breast health solutions, expected to close in the second or third quarter of 2025.

RadNet has entered into a definitive agreement to acquire iCAD, aiming to enhance AI-powered breast cancer detection and expand its global reach.

RadNet is hosting a media roundtable to discuss its acquisition of iCAD and the future of AI-powered early detection and diagnosis of breast cancer.